Original articles
Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xiaolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu, Fanghai Han, Junjian Wang. Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin[J]. Acta Pharmaceutica Sinica B, 2020, 10(12): 2313-2322

Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin
Jianwei Zhenga, Junfeng Wangb, Qian Wanga, Hongye Zouc, Hong Wanga, Zhenhua Zhanga, Jianghe Chena, Qianqian Wanga, Panxia Wanga, Yueshan Zhaoa, Jing Lua, Xiaolei Zhanga, Songtao Xiangd, Haibin Wange, Jinping Leia, Hong-Wu Chenc, Peiqing Liua,f,g, Yonghong Liub, Fanghai Hanh, Junjian Wanga,f,g
a School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China;
b CAS Key Laboratory of Tropical Marine Bio-resources and Ecology/Guangdong Key Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China;
c Department of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA;
d Department of Urology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China;
e Department of Joint Orthopaedic, the First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510405, China;
f National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation, Sun Yat-sen University, Guangzhou 510006, China;
g Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China;
h Department of Gastrointestinal Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Abstract:
antibiotic from Actinomycete streptomyces, is a novel RORγ antagonist and showed potent antitumor activity against CRPC in vitro and in vivo. We demonstrated that Elai selectively binded to RORγ protein and potently blocked RORγ transcriptional regulation activities. Structure-activity relationship studies showed that Elai occupied the binding pocket with several key interactions. Furthermore, Elai markedly reduced the recruitment of RORγ to its genomic DNA response element (RORE), suppressed the expression of RORγ target genes AR and AR variants, and significantly inhibited PCa cell growth. Importantly, Elai strongly suppressed tumor growth in both cell line based and patient-derived PCa xenograft models. Taken together, these results suggest that Elai is novel therapeutic RORγ inhibitor that can be used as a drug candidate for the treatment of human CRPC.
Key words:    RORγ    Castration-resistant prostate cancer    Nuclear receptor    Antagonist    Elaiophylin   
Received: 2020-03-13     Revised: 2020-06-20
DOI: 10.1016/j.apsb.2020.07.001
Funds: This research was supported by the National Natural Science Foundation of China (81872891, 81572925, 81774339 and 41776169), the Guangdong Natural Science Funds for Distinguished Young Scholar (No. 2019B151502016, China), the Science and Technology Planning Project of Guangdong Province (No. 2017A050506042, China), Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01Y093, China), National Major Special Projects for the Creation and Manufacture of New Drugs (2019ZX09301104, China), National Engineering and Technology Research Center for New drug Druggability Evaluation (Seed Program of Guangdong Province, 2017B090903004, China), the Fundamental Research Funds for the Central Universities (No. 19ykzd23, China), Pearl River S&T Nova Program of Guangzhou (No. 201710010136, China).
Corresponding author: Yonghong Liu, yonghongliu@scsio.ac.cn;fh_han@163.com;Fanghai Han, Junjian Wang, wangjj87@mail.sysu.edu.cn     Email:yonghongliu@scsio.ac.cn;fh_han@163.com;wangjj87@mail.sysu.edu.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Jianwei Zheng
Junfeng Wang
Qian Wang
Hongye Zou
Hong Wang
Zhenhua Zhang
Jianghe Chen
Qianqian Wang
Panxia Wang
Yueshan Zhao
Jing Lu
Xiaolei Zhang
Songtao Xiang
Haibin Wang
Jinping Lei
Hong-Wu Chen
Peiqing Liu
Yonghong Liu
Fanghai Han
Junjian Wang

References:
1. Lv G, Sun D, Zhang J, Xie X, Wu X, Fang W, et al. Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo. Acta Pharm Sin B 2017;7:52-8.
2. Chang AJ, Autio KA, Roachet MRd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol 2014;1:308-23.
3. Heidenreich A, Pfister D, Merseburgeret A, Bartsch G. Castrationresistant prostate cancer:where we stand in 2013 and what urologists should know. Eur Urol 2013;64:260-5.
4. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38.
5. Augello MA, Den RB, Knudsen KE. AR function in promoting metastatic prostate cancer. Canc Metastasis Rev 2014;33:399-411.
6. Efstathiou E, Titus M, Wenet S, Hoang A, Karlou M, Ashe R, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 2015;67:53-60.
7. Lu J, Van der Steen T, Tindall DJ. Are androgen receptor variants a substitute for the full-length receptor?. Nat Rev Urol 2015;12:137-44.
8. Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov 2014;13:197-216.
9. Solt LA, Burris TP. Action of RORs and their ligands in (patho) physiology. Trends Endocrinol Metabol 2012;23:619-27.
10. Sun N, Guo H, Wang Y. Retinoic acid receptor-related orphan receptor g-t (RORγt) inhibitors in clinical development for the treatment of autoimmune diseases:a patent review (2016epresent). Expert Opin Ther Pat 2019;29:663-74.
11. Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, et al. A validated regulatory network for Th17 cell specification. Cell 2012; 151:289-303.
12. Xiao S, Yosef N, Yang J, Wang Y, Zhou L, Zhu C, et al. Smallmolecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 2014;40:477-89.
13. Rene O, Fauber BP, Boenig Gde L, Burton B, Eidenschenk C, Everett C, et al. Minor structural change to tertiary sulfonamide RORc ligands led to opposite mechanisms of action. ACS Med Chem Lett 2015;6:276-81.
14. Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, et al. ROR-g drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med 2016;22:488-96.
15. Lytle NK, Ferguson LP, Rajbhandari N, Gilroy K, Fox RG, Deshpande A, et al. A multiscale map of the stem cell state in pancreatic adenocarcinoma. Cell 2019;177:572-86.
16. Cai D, Wang J, Gao B, Li J, Wu F, Zou JX, et al. RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. Nat Commun 2019;10:4621.
17. Cragg GM, Newman DJ. Natural products:a continuing source of novel drug leads. Biochim Biophys Acta 2013;1830:3670-95.
18. Zhi K, Wang J, Zhao H, Yang X. Self-assembled small molecule natural product gel for drug delivery:a breakthrough in new application of small molecule natural products. Acta Pharm Sin B 2020;10:913-27.
19. Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol 2011;4:687-99.
20. Lindequist U. Marine-derived pharmaceuticalsdchallenges and opportunities. Biomol Ther (Seoul) 2016;24:561-71.
21. Khalifa SAM, Elias N, Farag MA, Chen L, Saeed A, Hegazy MF, et al. Marine natural products:a source of novel anticancer drugs. Mar Drugs 2019;17:49.
22. Wu C, Tan Y, Gan M, Wang Y, Guan Y, Hu Y, et al. Identification of elaiophylin derivatives from the marine-derived Actinomycete streptomyces sp. 7-145 using PCR-based screening. J Nat Prod 2013;76:2153-7.
23. Wang J, Wang H, Wang LY, Cai D, Duan Z, Zhang Y, et al. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death Differ 2016;23:1886-96.
24. Lu J, Li J, Hu Y, Guo Z, Sun D, Wang P, et al. Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation. Acta Pharm Sin B 2019;9:782-93.
25. Lei J, Sheng G, Cheung PP, Wang S, Li Y, Gao X, et al. Two symmetric arginine residues play distinct roles in Thermus thermophilus Argonaute DNA guide strand-mediated DNA target cleavage. Proc Natl Acad Sci U S A 2019;116:845-53.
26. Lei J, Zhou Y, Xie D, Zhang Y. Mechanistic insights into a classic wonder drugdaspirin. J Am Chem Soc 2015;137:70-3.
27. Case DA, Darden TE, Cheatham III TE, Simmerling CL, Wang J, Duke RE, et al. AMBER 12. San Francisco:University of California; 2012. p. 79. Available from:https://ambermd.org/.
28. Zhang Y, Wu X, Xue X, Li C, Wang J, Wang R, et al. Discovery and characterization of XY101, a potent, selective, and orally bioavailable RORγ inverse agonist for treatment of castration-resistant prostate cancer. J Med Chem 2019;62:4716-30.
29. Zhao X, Fang Y, Yang Y, Qin Y, Wu P, Wang T, et al. Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells. Autophagy 2015;11:1849-63.
30. Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Evans CP, et al. Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells. Am J Clin Exp Urol 2019;7:203-14.
31. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
32. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
33. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Canc Cell 2010;18:11-22.
34. Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer:progresses and prospects. Oncogene 2015;34:1745-57.
35. Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara Jr PN, et al. Targeting autophagy overcomes enzalutamide resistance in castrationresistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene 2014;33:4521-30.
36. Kranzbuhler B, Salemi S, Mortezavi A, Sulser T, Eberli D. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells. Prostate 2019;79:206-14.
Similar articles: